Evidence map›Paper›PMID 42706534›Full record

ArticleJournal of translational medicine2026

Enhancer-mediated DDIT4 activation by SMYD2-dependent H3K4me1 promotes pazopanib resistance in clear cell renal cell carcinoma.

Yun Sun, Mengyao Wang, Haoran Song, Yi Wu, Yingxia He, Fumin Ma, Yuxuan Liang, Lishuo Zhang, Jianan Gong, Minghua Ren and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yun Sun *Department of Cell Biology, Harbin Medical University, No. 196 Baojian Road, Nangang District, Harbin, Heilongjiang, 150081, China.
Mengyao Wang *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Haoran Song *Department of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Yi WuDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Yingxia HeDepartment of Cell Biology, Harbin Medical University, No. 196 Baojian Road, Nangang District, Harbin, Heilongjiang, 150081, China.
Fumin MaDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Yuxuan LiangDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Lishuo ZhangDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Jianan GongDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Minghua RenDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China.
Zhaohua ZhongDepartment of Microbiology, Harbin Medical University, Harbin, 150081, China.
Wenran ZhaoDepartment of Cell Biology, Harbin Medical University, No. 196 Baojian Road, Nangang District, Harbin, Heilongjiang, 150081, China. zhaowr@hrbmu.edu.cn.
Beichen DingDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin, Heilongjiang, 150001, China. dingbeichen@hrbmu.edu.cn.

Funding

National Natural Science Foundation of China 82002680Natural Science Foundation of Heilongjiang Province YQ2024H012Program for Young Talents of Basic Research in Universities of Heilongjiang Province 2024127
6 · The paper itself

Abstract

backgroundThe progression and resistance to targeted therapy, including pazopanib, frequently lead to poor prognosis in clear cell renal cell carcinoma (ccRCC) patients. However, the underlying molecular mechanisms of these processes remain unclear.

methodsIn this study, we first performed RNA-seq to identify genes that were differentially expressed in both SMYD2-knockdown and pazopanib-resistant cells, indicating their potential role in SMYD2-mediated drug resistance. We analyzed TCGA-KIRC data and 150 patient samples to identify the relationship between SMYD2 and DDIT4 expression levels, as well as the prognostic significance of DDIT4. In vitro functional assays and murine models were applied to evaluate the effects of SMYD2 and DDIT4 on tumor growth and on pazopanib resistance. CUT&Tag and chromosome conformation capture (4 C) assays were applied to identify enhancers associated with SMYD2-mediated regulation of DDIT4, while the JASPAR database was utilized to predict transcription factors involved in the enhancer regulation. CRISPR-mediated enhancer deletion and ChIP-qPCR were subsequently performed to validate the regulatory roles of the identified enhancer and the transcription factor SPI1 in DDIT4 expression.

resultsOur study revealed that the expression level of DDIT4 is positively correlated with SMYD2. DDIT4 is highly expressed in renal cell carcinoma and is associated with poorer survival outcomes. Further research revealed that SMYD2 regulates H3K4me1 in a DDIT4 distal enhancer (chr10:72830412-72830891), promoting the recruitment of the transcription factor SPI1, thereby activating DDIT4 expression. We found that DDIT4 promotes the proliferation, metastasis, and pazopanib resistance of ccRCC, and DDIT4 knockdown enhances drug sensitivity in both in vitro and in vivo experiments. Furthermore, the SMYD2-DDIT4 axis activates the downstream STAT3 signaling pathway, thereby promoting tumor progression. In addition, DDIT4-related prognostic features showed potential associations with patient survival and predicted drug sensitivity in computational analyses.

conclusionsOur study identifies a previously unrecognized SMYD2-enhancer-DDIT4 regulatory axis, which promotes tumor progression and pazopanib resistance in ccRCC. These findings may provide potential therapeutic implications to overcome pazopanib resistance and improve treatment outcomes in ccRCC by targeting the SMYD2-enhancer-DDIT4 axis.

Indexed as

Carcinoma, Renal CellDrug Resistance, NeoplasmEnhancer Elements, GeneticHistone-Lysine N-MethyltransferaseHistonesKidney NeoplasmsPyrimidinesSulfonamidesTranscription FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansIndazolesMice, NudeDDIT4 protein, humanH3K4me1Histone-Lysine N-MethyltransferaseHistonesIndazolespazopanibPyrimidinesSMYD2 protein, humanSulfonamidesTranscription FactorsccRCCDDIT4Enhancer regulationPazopanib resistanceSMYD2STAT3 signaling

Identifiers

PMID42706534
PMCPMC13551884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.